The Experts below are selected from a list of 939 Experts worldwide ranked by ideXlab platform
Hong-jin Kim - One of the best experts on this subject based on the ideXlab platform.
-
Comparison between of the attenuated BR-Oka and the wild type strain of Varicella Zoster Virus (VZV) on the DNA level
Archives of Pharmacal Research, 2000Co-Authors: Sang-min Lim, Seong-won Song, Sang-lin Kim, Yoon-jung Jang, Ki-ho Kim, Hong-jin KimAbstract:Oka strain VR-795 (Varicella Zoster Virus, VZV) of American Type Culture Collection (ATCC) has been used for Chickenpox Vaccine production. In order to use this strain for Vaccine production, the strain must be identified and its stability must be confirmed. The identification of the Oka strain has been confirmed using Restriction Fragment Length Polymorphism (RFLP) and DNA sequence analysis of glycoprotein-II (gp-II). The amino acid sequences of Oka deduced from the DNA sequence of gp-II have changed at three amino acids against Ellen and at one amino acid against Webster. To prove the stability of the Oka strain during the passage, RFLP and DNA sequence analyses were also used with 11, 15 and 23 times of virus passage. We found that the Oka strain was stable at passages of up to 23 times, based on the RFLP and DNA sequence analyses. The confirmed Oka strain was renamed as BR-Oka for the purposes of Chickenpox Vaccine production.
Ellen Rafferty - One of the best experts on this subject based on the ideXlab platform.
-
what we know now an economic evaluation of Chickenpox vaccination and dose timing using an agent based model
Value in Health, 2020Co-Authors: Ellen Rafferty, Wade Mcdonald, Nathaniel D Osgood, Alexander Doroshenko, Marwa FaragAbstract:Abstract Objectives The value of Chickenpox vaccination is still debated in the literature and by jurisdictions worldwide. This uncertainty is reflected in the inconsistent uptake of the Vaccine, where some countries offer routine childhood immunization programs, others have targeted programs, and in many the Vaccine is only privately available. Even across the countries that have universal funding for the Vaccine, there is a diversity of schedules and dosing intervals. Using an agent-based model of Chickenpox and shingles, we conducted an economic evaluation of Chickenpox vaccination in Alberta, Canada. Methods We compared the cost-effectiveness of 2 common Chickenpox vaccination schedules, specifically a long dosing interval (first dose: 12 months; second dose: 4-6 years) and a short dosing interval (first dose: 12 months; second dose: 18 months). Results The economic evaluation demonstrated a shorter dosing interval may be marginally preferred, although it consistently led to higher costs from both the societal and healthcare perspectives. We found that Chickenpox vaccination would be cost-saving and highly cost-effective from the societal and healthcare perspective, assuming there was no impact on shingles. Conclusion Chickenpox Vaccine was cost-effective when not considering shingles and remained so even if there was a minor increase in shingles following vaccination. However, if Chickenpox vaccination did lead to a substantial increase in shingles, then Chickenpox vaccination was not cost-effective from the healthcare perspective.
-
seeking the optimal schedule for Chickenpox vaccination in canada using an agent based model to explore the impact of dose timing coverage and waning of immunity on disease outcomes
Vaccine, 2020Co-Authors: Ellen Rafferty, Wade Mcdonald, Nathaniel D Osgood, Weicheng Qian, Alexander DoroshenkoAbstract:Abstract Many countries continue to consider implementing a universal Chickenpox Vaccine program; however, there is no consensus on the most appropriate and effective timing between Vaccine doses. The Chickenpox Vaccine schedule debate is highlighted in Canada, where there are currently eight different Vaccine schedules across the country. The objective of this study was to test the overall effectiveness of Chickenpox vaccination, as well as the specific impact of two different Vaccine schedules, on Chickenpox disease outcomes in Alberta over 75 years. Using an agent-based model of Chickenpox disease, we tested the impact of three vaccination scenarios including: baseline (no vaccination), a long dosing interval-Schedule LDI (1st dose – 12 months; 2nd dose – 4-6 years) and a short dosing interval-Schedule SDI (1st dose – 12 months; 2nd dose – 18 months) on Chickenpox and shingles disease outcomes. Chickenpox vaccination led to a substantial decrease in Chickenpox incidence over 75 years post-Vaccine implementation. Compared to Schedule LDI, Schedule SDI resulted in a significantly lower Chickenpox incidence, a higher age of Chickenpox infection, a lower Chickenpox breakthrough rate and a higher shingles incidence rate. Our model findings suggest that the Chickenpox Vaccine is effective over a long period of time and the dose timing of the Vaccine may impact disease outcomes and Vaccine effectiveness. However, the effectiveness of the Vaccine dose timing is only one consideration for policy-makers who are implementing a Chickenpox Vaccine program, with others including risk of adverse events, the impact of the schedule on other antigens in a combination Vaccine, parental acceptance and the cost associated with different schedules.
Alexander Doroshenko - One of the best experts on this subject based on the ideXlab platform.
-
what we know now an economic evaluation of Chickenpox vaccination and dose timing using an agent based model
Value in Health, 2020Co-Authors: Ellen Rafferty, Wade Mcdonald, Nathaniel D Osgood, Alexander Doroshenko, Marwa FaragAbstract:Abstract Objectives The value of Chickenpox vaccination is still debated in the literature and by jurisdictions worldwide. This uncertainty is reflected in the inconsistent uptake of the Vaccine, where some countries offer routine childhood immunization programs, others have targeted programs, and in many the Vaccine is only privately available. Even across the countries that have universal funding for the Vaccine, there is a diversity of schedules and dosing intervals. Using an agent-based model of Chickenpox and shingles, we conducted an economic evaluation of Chickenpox vaccination in Alberta, Canada. Methods We compared the cost-effectiveness of 2 common Chickenpox vaccination schedules, specifically a long dosing interval (first dose: 12 months; second dose: 4-6 years) and a short dosing interval (first dose: 12 months; second dose: 18 months). Results The economic evaluation demonstrated a shorter dosing interval may be marginally preferred, although it consistently led to higher costs from both the societal and healthcare perspectives. We found that Chickenpox vaccination would be cost-saving and highly cost-effective from the societal and healthcare perspective, assuming there was no impact on shingles. Conclusion Chickenpox Vaccine was cost-effective when not considering shingles and remained so even if there was a minor increase in shingles following vaccination. However, if Chickenpox vaccination did lead to a substantial increase in shingles, then Chickenpox vaccination was not cost-effective from the healthcare perspective.
-
seeking the optimal schedule for Chickenpox vaccination in canada using an agent based model to explore the impact of dose timing coverage and waning of immunity on disease outcomes
Vaccine, 2020Co-Authors: Ellen Rafferty, Wade Mcdonald, Nathaniel D Osgood, Weicheng Qian, Alexander DoroshenkoAbstract:Abstract Many countries continue to consider implementing a universal Chickenpox Vaccine program; however, there is no consensus on the most appropriate and effective timing between Vaccine doses. The Chickenpox Vaccine schedule debate is highlighted in Canada, where there are currently eight different Vaccine schedules across the country. The objective of this study was to test the overall effectiveness of Chickenpox vaccination, as well as the specific impact of two different Vaccine schedules, on Chickenpox disease outcomes in Alberta over 75 years. Using an agent-based model of Chickenpox disease, we tested the impact of three vaccination scenarios including: baseline (no vaccination), a long dosing interval-Schedule LDI (1st dose – 12 months; 2nd dose – 4-6 years) and a short dosing interval-Schedule SDI (1st dose – 12 months; 2nd dose – 18 months) on Chickenpox and shingles disease outcomes. Chickenpox vaccination led to a substantial decrease in Chickenpox incidence over 75 years post-Vaccine implementation. Compared to Schedule LDI, Schedule SDI resulted in a significantly lower Chickenpox incidence, a higher age of Chickenpox infection, a lower Chickenpox breakthrough rate and a higher shingles incidence rate. Our model findings suggest that the Chickenpox Vaccine is effective over a long period of time and the dose timing of the Vaccine may impact disease outcomes and Vaccine effectiveness. However, the effectiveness of the Vaccine dose timing is only one consideration for policy-makers who are implementing a Chickenpox Vaccine program, with others including risk of adverse events, the impact of the schedule on other antigens in a combination Vaccine, parental acceptance and the cost associated with different schedules.
Anders Tegnell - One of the best experts on this subject based on the ideXlab platform.
-
The burden of Chickenpox disease in Sweden
BMC infectious diseases, 2016Co-Authors: Katarina Widgren, Johan Giesecke, Lars Lindquist, Anders TegnellAbstract:Chickenpox Vaccine is not included in the routine childhood vaccination programme in Sweden. The aim of this study was to estimate the baseline of national Chickenpox disease burden, as comprehensive studies, required for an assessment regarding Vaccine introduction, are lacking. We used available health care registers and databases; the death register, hospitalisations register, communicable disease notifications database, Stockholm County registers on consultations in specialist and primary care, temporary parental benefit to care for a sick child, and searches on the health care system’s website. From each data source, records regarding Chickenpox were identified and extracted, either using relevant diagnosis codes (ICD-10) or key words. A descriptive analysis with regards to number of cases and incidence, severity, and seasonality, was carried out covering the time period 2007 to 2013. There were on average 333 patients hospitalised annually due to Chickenpox, yielding a hospitalisation rate of 3.56/100,000 person-years. We found a slight male predominance in hospitalised cases. The highest hospitalisation rate was seen in 1 year-olds, whereas the peak in primary care consultations was in 2 year-olds. Nearly a quarter of children had parents who reported absence from work to care for them when sick with Chickenpox. The average yearly death rate from Chickenpox was 0.034/100,000 person-years. The duration of hospital stay increased with age. The seasonality in number of searches on the health care website corresponded well with hospitalisations and primary care consultations with peaks in spring. This study shows Chickenpox death and hospitalisation rates in range with other European countries without routine vaccination. Swedish children fall ill with Chickenpox at a very young age. The study provides essential input for future discussions on the introduction of routine Chickenpox vaccination in Sweden.
-
The burden of Chickenpox disease in Sweden
BMC Infectious Diseases, 2016Co-Authors: Katarina Widgren, Johan Giesecke, Lars Lindquist, Anders TegnellAbstract:Background Chickenpox Vaccine is not included in the routine childhood vaccination programme in Sweden. The aim of this study was to estimate the baseline of national Chickenpox disease burden, as comprehensive studies, required for an assessment regarding Vaccine introduction, are lacking. Methods We used available health care registers and databases; the death register, hospitalisations register, communicable disease notifications database, Stockholm County registers on consultations in specialist and primary care, temporary parental benefit to care for a sick child, and searches on the health care system’s website. From each data source, records regarding Chickenpox were identified and extracted, either using relevant diagnosis codes (ICD-10) or key words. A descriptive analysis with regards to number of cases and incidence, severity, and seasonality, was carried out covering the time period 2007 to 2013. Results There were on average 333 patients hospitalised annually due to Chickenpox, yielding a hospitalisation rate of 3.56/100,000 person-years. We found a slight male predominance in hospitalised cases. The highest hospitalisation rate was seen in 1 year-olds, whereas the peak in primary care consultations was in 2 year-olds. Nearly a quarter of children had parents who reported absence from work to care for them when sick with Chickenpox. The average yearly death rate from Chickenpox was 0.034/100,000 person-years. The duration of hospital stay increased with age. The seasonality in number of searches on the health care website corresponded well with hospitalisations and primary care consultations with peaks in spring. Conclusions This study shows Chickenpox death and hospitalisation rates in range with other European countries without routine vaccination. Swedish children fall ill with Chickenpox at a very young age. The study provides essential input for future discussions on the introduction of routine Chickenpox vaccination in Sweden.
Sang-min Lim - One of the best experts on this subject based on the ideXlab platform.
-
Comparison between of the attenuated BR-Oka and the wild type strain of Varicella Zoster Virus (VZV) on the DNA level
Archives of Pharmacal Research, 2000Co-Authors: Sang-min Lim, Seong-won Song, Sang-lin Kim, Yoon-jung Jang, Ki-ho Kim, Hong-jin KimAbstract:Oka strain VR-795 (Varicella Zoster Virus, VZV) of American Type Culture Collection (ATCC) has been used for Chickenpox Vaccine production. In order to use this strain for Vaccine production, the strain must be identified and its stability must be confirmed. The identification of the Oka strain has been confirmed using Restriction Fragment Length Polymorphism (RFLP) and DNA sequence analysis of glycoprotein-II (gp-II). The amino acid sequences of Oka deduced from the DNA sequence of gp-II have changed at three amino acids against Ellen and at one amino acid against Webster. To prove the stability of the Oka strain during the passage, RFLP and DNA sequence analyses were also used with 11, 15 and 23 times of virus passage. We found that the Oka strain was stable at passages of up to 23 times, based on the RFLP and DNA sequence analyses. The confirmed Oka strain was renamed as BR-Oka for the purposes of Chickenpox Vaccine production.